Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13770429 | 0.86 | MGLL (0.31) | MGLLSLC1A2CA12CA14 | |
| SCHEMBL8641759 | 0.83 | TAS1R3 (0.33) | MGLLSLC1A2 | |
| SCHEMBL25413295 | 0.83 | DPP4 (0.35) | MGLLDPP4SLC1A2 | |
| SCHEMBL10308400 | 0.83 | DPP4 (0.35) | MGLLDPP4SLC1A2 | |
| SCHEMBL22571836 | 0.82 | MGLL (0.33) | MGLL | |
| SCHEMBL1985368 | 0.82 | SMN1; SMN2 (0.35) | CA12CA14 | |
| SCHEMBL1985371 | 0.82 | SMN1; SMN2 (0.35) | CA12CA14 | |
| SCHEMBL20608691 | 0.81 | SMN1; SMN2 (0.43) | CA12CA14 | |
| SCHEMBL20608692 | 0.81 | SMN1; SMN2 (0.43) | CA12CA14 | |
| SCHEMBL7393144 | 0.79 | BRD4 (0.31) | SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233703-A1 | AMANITIN CONJUGATES | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233703-A1 | AMANITIN CONJUGATES | CD47, MTX1, SIGLEC7 | MGLL 4446/4885DPP4 1925/4885SLC1A2 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.